Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar.

Similarly, in EMBARK [ 9 , 10 ], although the primary endpoint of NSAA change at 52 weeks did not reach statistical significance across the cohort, subsets of patients showed clinically meaningful improvements in NSAA and timed function tests.

also in 111,027 other papers